Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

788.19 -1.13 (-0.14%)
Official Closing Price Updated: 4:10 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
2 Healthcare Stocks to Buy Hand Over Fist in August
These longtime winners still have a lot to offer. 
Via The Motley Fool
S&P 500 Records Best Session Since January 2023: Investor Sentiment Improves, But Greed Index Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly Shatters Q2 Estimates, Boosts Annual Guidance on Mounjaro and Zepbound Surge
Eli Lilly Shatters Q2 Estimates, Boosts Annual Guidance on Mounjaro and Zepbound Surge 
Via Chartmill
Eli Lilly (LLY) Q2 2024 Earnings Call Transcript
LLY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Eli Lilly Stock Just Jumped 8%
How fast must Lilly grow to justify a 54.5 P/E ratio? 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound, Mounjaro Sales Boom
Drug giant also raises guidance. Lilly stock soared. 
Via Investor's Business Daily
Before the Bell: Eli Lilly Presents its Q2 Results
Before the Bell: Eli Lilly Presents its Q2 Results 
Via Chartmill
Dow Jumps Over 500 Points; Eli Lilly Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Eli Lilly And Company Shines In Q2 With $11.30B Revenue, 68% EPS Growth
Eli Lilly and Company has reported a strong financial performance for the second quarter of 2024, with revenue reaching $11.30 billion. 
Via Talk Markets
LLY Stock Alert: Why Are Eli Lilly Shares Surging Today?
Eli Lilly's growth should accelerate now that shortages of its GLP-1 drugs are resolved, but competitors are coming. 
Via InvestorPlace
Mounjaro Maker Eli Lilly's Bumper Q2 Earnings Exceeds Estimates, Hikes Outlook Again On Strong Diabetes And Weight Loss Drugs Sales
Eli Lilly's Q2 revenue surged 36% year-over-year to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and other key drugs. The company raised its 2024 sales and EPS guidance, citing improved... 
Via Benzinga
Bears Betting Against Nvidia And Eli Lilly For 'Easy Money,' Says Jim Cramer: 'Those Are The Two Keys To This Market And Don't You Know It'
Jim Cramer has issued a warning about the bearish pressure on NVIDIA Corp. and Eli Lilly and Co, stating that these two companies are crucial to the market's performance. 
Via Benzinga
US Stocks Decline As SMCI's Margin Miss Brings Nvidia And Other AI Stocks Under Pressure: Investor Sentiment Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly, US Foods And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings
Eli Lilly (LLY) reports Q2 earnings on Thursday with expected EPS of $2.70 and $9.9B in revenues. Stock shows bearish trend but analysts predict 15% upside. 
Via Benzinga
What's Going On With Eli Lilly And Company Shares Wednesday?
Eli Lilly is anticipated to release earnings 2024 fiscal year earnings on Thursday before the market opens. 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
Some investors may be eyeing potential gains from the company's dividends. Here's how you can earn $500 monthly from Eli Lilly. 
Via Benzinga
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy. 
Via The Motley Fool
Novo Nordisk Tumbles 3% In Wednesday Premarket: What's Causing 'Miracle' Weight Loss Drug Ozempic Maker's Stock Slide?
The dip in Novo Nordisk's shares comes despite deep-pocketed investors were adopting a bullish approach. 
Via Benzinga
Prediction: This Will Be the Best Pharmaceutical Stock to Own Over the Next 10 Years
Eli Lilly is one of the most innovative pharmaceutical companies right now. 
Via The Motley Fool
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These tried-and-true businesses can deliver returns to investors for many years to come. 
Via The Motley Fool
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly's Zepbound and Novo Nordisk's Wegovy face supply shortages, influencing doctors' prescribing habits. Both companies are investing heavily to meet demand in the lucrative U.S. market. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.